

Amendments to the Claims:

Please cancel claim 4, 7 to 11 and 18 to 23.

Listing of the Claims:

This listing of claims replaces all prior versions and listings of the claims in the application.

1-4. (Cancelled).

5. (Previously presented): A composition for the treatment of glaucoma and ocular hypertension comprising a therapeutically active and physiologically acceptable amount of a prostaglandin analog which is a selective agonist for EP₁ prostanoid receptors, or a pharmaceutically acceptable salt or ester thereof, wherein the prostaglandin analog is 13,14-dihydro-17-(3-fluorophenyl)-18,19,20-trinor-PGE₂ or an alkyl ester thereof, and an ophthalmologically-compatible vehicle, wherein the composition is adapted for topical application to the eye.

6-23. (Cancelled).